Bruker Management
Management criteria checks 3/4
Bruker's CEO is Frank Laukien, appointed in Feb 1991, has a tenure of 35.58 years. total yearly compensation is $4.71M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 26.53% of the company’s shares, worth €1.86B. The average tenure of the management team and the board of directors is 13.7 years and 10.8 years respectively.
Key information
Frank Laukien
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 20.75% |
| CEO tenure | 35.6yrs |
| CEO ownership | 26.5% |
| Management average tenure | 13.7yrs |
| Board average tenure | 10.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$107m |
| Mar 31 2026 | n/a | n/a | -US$36m |
| Dec 31 2025 | US$5m | US$977k | -US$22m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | US$80m |
| Mar 31 2025 | n/a | n/a | US$80m |
| Dec 31 2024 | US$6m | US$966k | US$113m |
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
Compensation vs Market: Frank's total compensation ($USD4.71M) is above average for companies of similar size in the German market ($USD2.71M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
CEO
Frank Laukien (66 yo)
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation since February 1991. Dr. Laukien serves as the Chairman, Chief Executive Officer and Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 35.6yrs | US$4.71m | 26.53% € 1.9b | |
| Executive VP & CFO | 8.5yrs | US$2.01m | 0.040% € 2.8m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 14yrs | US$2.18m | 0.060% € 4.2m | |
| President of Bruker Biosystems Group & Bruker Daltonics Division | 13.7yrs | US$1.42m | 0.096% € 6.7m | |
| Chief Accounting Officer | 1.7yrs | no data | 0.00064% € 44.9k | |
| Senior VP | no data | no data | no data | |
| President of Bruker Microbiology & Infection Diagnostics Group | less than a year | no data | no data | |
| President and CEO of Bruker Energy & Supercon Technologies | 18.4yrs | US$967.91k | 0.013% € 884.6k |
Experienced Management: BKD's management team is seasoned and experienced (13.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 35.6yrs | US$4.71m | 26.53% € 1.9b | |
| Independent Director | 11.1yrs | US$272.53k | 0.023% € 1.6m | |
| Independent Director | 10.8yrs | US$260.20k | 0.022% € 1.6m | |
| Lead Director | 19.3yrs | US$263.37k | 0.059% € 4.1m | |
| Independent Director | 26.6yrs | US$252.95k | 0.039% € 2.7m | |
| Independent Director | 1.6yrs | US$243.35k | no data | |
| Independent Director | 9.3yrs | US$252.03k | 0.016% € 1.1m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 11.1yrs | US$247.62k | 0.017% € 1.2m | |
| Independent Director | 6yrs | US$258.45k | 0.0088% € 614.3k | |
| Independent Director | less than a year | no data | 0% € 0 |
Experienced Board: BKD's board of directors are seasoned and experienced ( 10.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 21:57 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bruker Corporation is covered by 34 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Lu Li | BofA Global Research |
| Michael Ryskin | BofA Global Research |